Protagen Receives CE Mark for BICD2 Systemic Sclerosis Marker | GenomeWeb

NEW YORK (GenomeWeb) – Protagen said today that it has received the CE mark for its Multilisa BICD2 test for diagnosing systemic sclerosis, enabling the firm to market the test in the European Union and other countries that accept the CE mark.

The announcement follows the release last month of Protagen's CE-marked Multilisa CENP-B and Multilisa Scl70 assays, giving the company what CEO Stefan Müllner called "a comprehensive assay portfolio for the improvement of [systemic sclerosis] diagnosis and patient care."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.